Emerging therapies in thoracic malignancies— immuno the rapy, targe ted the rapy, and t-cell the rapy in non–small cell lung cancer

Abstract

Over the past decade there have been dramatic therapeutic advances for non–small cell lung cancer (NSCLC) that have been based on an improved understanding of biomarkers, tumor immunology, driver mutations, T-cell receptors (TCRs), and adoptive immune therapies. As a result of these advances, the overall survival (OS) currently seen with immunotherapy and targeted biologic regimens is remarkably longer than with historic cytotoxic chemotherapy. These discoveries have created many new possible therapeutic options for lung cancer patients in both local and metastatic settings. This article reviews the current landscape of immunotherapy, targeted therapy, and adoptive therapy in NSCLC.